Masimo

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo

Purchases

+Additional Purchases

Sales

+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:




There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com

On July 17, 2023, Masimo, a company, released its preliminary revenue results for the second quarter of 2023. They projected their revenue to be between $453 million and $457 million, which is significantly lower than the estimated $540.87 million. The decrease in revenue was attributed to various factors, including delays in large orders, declining sales of single-patient use sensors, reduced customer conversions, and a decrease in demand for their products from hospitals.

As a consequence of this announcement, Masimo’s stock price experienced a sharp decline from $147.16 per share on July 17, 2023, to $117.73 per share on July 18, 2023. The stock fell by $29.43 per share in response to the lower-than-expected revenue forecast.